Table 4 Dynamics of clinical tests in patients with COVID-19 at two-time points (n = 10)
From: Intriguing findings of liver fibrosis following COVID-19
Parameters | Acute COVID-19 (baseline) | Post-COVID | z | p | η2 |
|---|---|---|---|---|---|
WBC, × 103/µl (IQR) | 5.39 (4.21; 6.95) | 4.86 (4.63; 6.70) | − 0.56 | 0.575 | 0.03 |
RBC, × 106/µl (IQR) | 4.47 (4.35; 4.74) | 4.69 (4.57; 4.89) | − 2.30 | 0.022 | 0.53 |
PLT, × 103/µl (IQR) | 205 (162; 245) | 260 (230; 285) | − 1.96 | 0.051 | 0.38 |
ESR, mm/h | 19 (12; 43) | 2 (2; 5) | − 2.37 | 0.018 | 0.56 |
ALT, U/l (IQR) | 21 (12; 47) | 25 (16; 35) | − 0.05 | 0.959 | 0.00 |
AST, U/l (IQR) | 23 (20; 42) | 19 (16; 26) | − 1.94 | 0.052 | 0.38 |
FIB-4 (IQR) | 0.99 (0.74; 3.11) | 0.65 (0.45; 0.89) | − 2.19 | 0.028 | 0.48 |
CRP, mg/l (IQR) | 30.64 (3.30; 56.89) | 1.92 (1.03; 5.44) | − 2.70 | 0.007 | 0.73 |
Creatinine, µmol/l (IQR) | 79 (57; 91) | 73 (63; 82) | − 0.42 | 0.678 | 0.02 |